dc.contributor.author |
Intthira Thiangkrathok |
|
dc.contributor.author |
Nattha Laobankho |
|
dc.contributor.author |
Thunpitcha Pilasopa |
|
dc.contributor.author |
Phurit Thanarangsarit |
|
dc.contributor.author |
อินทิรา เที่ยงกระโทก |
|
dc.contributor.author |
ณัฐฐา เหล่าบ้านค้อ |
|
dc.contributor.author |
ธัญพิชชา พิลาโสภา |
|
dc.contributor.author |
ภูริต ธนะรังสฤษฏ์ |
|
dc.contributor.other |
Huachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences. Student of Bachelor of Pharmaceutical Sciences |
en |
dc.contributor.other |
Huachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences. Student of Bachelor of Pharmaceutical Sciences |
en |
dc.contributor.other |
Huachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences. Student of Bachelor of Pharmaceutical Sciences |
en |
dc.contributor.other |
Huachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences |
en |
dc.date.accessioned |
2024-12-04T11:53:47Z |
|
dc.date.available |
2024-12-04T11:53:47Z |
|
dc.date.issued |
2024 |
|
dc.identifier.uri |
https://has.hcu.ac.th/jspui/handle/123456789/3345 |
|
dc.description |
Proceedings of the 11th National and International Conference on "Research to Serve Society", 26 June 2024 at Huachiew Chalermprakiet University, Bangphli District, Samutprakarn, Thailand. p. 475-482. |
en |
dc.description.abstract |
The aim of this study is to develop a secondary standard of favipiravir from favipiravir tablets for a replacement of costly reference standard. Firstly, favipiravir was isolated and purified from the powdered tablets by liquid-liquid extraction method using ethyl acetate and water. The total amount of extracted favipiravir yield 31.25% and the extract was consequently identified using Fourier-transform infrared (FT-IR) spectroscopy. Secondly, quantity or purity of extracted favipiravir was determined using a validated ultraviolet (UV)-visible spectrophotometric method. The analysis result showed that the purity of favipiravir was 95.98% (as is) which the acceptance criteria has been limited within 98.0-102.0%. Unfortunately, although the purity of developed favipiravir secondary standard was nearly met the criteria, it could be preliminary used as a standard substance in some routine pharmaceutical laboratory procedures, such as identification, in-process quality control, including pharmacological studies. |
en |
dc.language.iso |
en_US |
en |
dc.rights |
มหาวิทยาลัยหัวเฉียวเฉลิมพระเกียรติ |
en |
dc.subject |
Secondary Standard |
en |
dc.subject |
สารมาตรฐานทุติยภูมิ |
en |
dc.subject |
Favipiravir |
en |
dc.subject |
ฟาวิพิราเวียร์ |
en |
dc.subject |
COVID-19 (Disease) |
en |
dc.subject |
โควิด-19 (โรค) |
en |
dc.subject |
COVID-19 Pandemic, 2020- |
en |
dc.subject |
การระบาดใหญ่ของโควิด-19, ค.ศ. 2020- |
en |
dc.subject |
UV-visible spectrophotometry |
en |
dc.subject |
อัลตราไวโอเลต-วิสิเบิลเสปกโทรโฟโตมิเตอร์ |
en |
dc.title |
Development of Favipiravir Secondary Standard from Favipiravir Tablets |
en |
dc.type |
Proceeding Document |
en |